Brooks D J, Forsyth D, Playfer J R, Williams A C
Imperial College School of Medicine, Hammersmith Hospital, London.
Hosp Med. 2000 Apr;61(4):267-71. doi: 10.12968/hosp.2000.61.4.1315.
Catechol-O-methyltransferase (COMT) inhibition is an important advance in the treatment of Parkinson's disease. This consensus statement provides guidelines for the optimal use of the only currently available COMT inhibitor, entacapone (Comtess, Orion Pharma (UK) Ltd, Newbury, Berkshire).
